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Abstract
Background The median age of patients diagnosed with
essential thrombocythaemia (ET) is 65–70 years but the
management of very elderly patients (aged[80 years) with
ET has not been well characterized.
Objective This study aimed to document the treatment
patterns of very elderly patients with ET in a multinational,
real-world setting.
Study Design EXELS (Evaluation of Xagrid Efficacy and
Long-term Safety) is a phase IV observational study,
designed to monitor the efficacy and safety of cytoreduc-
tive therapies in clinical practice. In total, 3,598 high-risk
patients with ET were recruited from May 2005 to April
2009, in 13 European countries. Data were collected at
registration and every 6 months thereafter for 5 years. This
analysis was performed on a data-cut taken approximately
2 years after the last patient was registered.
Patients In total, 395 patients aged [80 years at regis-
tration into EXELS were included in the analysis; of these,
42.2 % had experienced a previous thrombohaemorrhagic
event.
Results At registration, the most frequently prescribed
cytoreductive therapy for patients aged [80 years was
hydroxycarbamide (HC), which accounted for 82.8 % of
patients whereas anagrelide use was less frequent (8.6 %).
Very elderly patients were more likely to be switched from
anagrelide than from HC (47.1 vs. 17.4 %; 95 % confi-
dence interval for difference in proportion 12.4–46.9; Chi-
squared test p \ 0.001). Median platelet count during
treatment was *430 9 109/L. In patients aged[80 years,
the main reason for switch was intolerance/side effects
(34.1 %); 0/16 patients reported treatment with anagrelide
was non-efficacious compared with 8/57 (14 %) patients
receiving HC, and 7/16 (43.8 %) anagrelide patients swit-
ched because of intolerance versus 18/57 (31.6 %) patients
receiving HC. At least one predefined clinical event (PDE)
was experienced by 27.3 % of patients aged [80 years.
The most common PDEs reported in the very elderly age
group were death (non-PDE related; 11.1 %), other car-
diovascular symptoms (5.8 %), haematological transfor-
mation (3.8 %), congestive heart failure (3.3 %),
myocardial infarction and angina (2.8 %), and thrombo-
embolic events (6.3 %).
Conclusion Well-tolerated and effective cytoreductive
therapy has been achieved in patients aged [80 years by
following individual treatment modalities that appear in
agreement with the recent European LeukemiaNet (ELN)
guidelines.
Clinical Trial Registration Registered as ClinicalTri-
als.gov identifier NCT00567502; Protocol No: SPD422-401.
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1 Introduction
Essential thrombocythaemia (ET) is a chronic myelopro-
liferative neoplasm (MPN) characterized by the overpro-
duction of platelets by megakaryocytes [1]. The median
age at diagnosis of ET is approximately 65–70 years with
its incidence increasing with age [2, 3]. Previous retro-
spective studies suggest that patients with ET aged
[60 years have an increased risk of thrombotic events [4,
5]. However, previous randomized controlled trials suggest
that thrombosis risk is reduced when patients are treated
with cytoreductive therapy [6, 7]. Thus, according to
international guidelines, high-risk patients with ET
(patients [60 years of age; history of thrombohaemor-
rhagic events; initial platelet count[1500 9 109/L) should
be considered for cytoreductive therapy [8].
Hydroxycarbamide (HC) is currently recommended for
first-line therapy in high-risk patients with ET of all ages,
although it should be used with caution in patients aged
\40 years [8]. Anagrelide is approved for second-line
treatment of ET in Europe [9]. Both HC and anagrelide
have been used in patients with a wide range of ages [6,
10–17]. Since the overall population with ET are of
advanced age, we believe it would be of value to more
closely assess the very elderly patients (aged [80 years),
for whom different treatment decisions may be appro-
priate. Elderly patients are known to have greater
thrombotic risk than younger patients in the general
population [18] and this risk is already increased in
patients with ET. To date, there has been limited infor-
mation reported regarding treatment practice in very
elderly patients with ET [19].
EXELS (Evaluation of Xagrid Efficacy and Long-term
Safety) is a phase IV study, designed to monitor the safety
of anagrelide and other cytoreductive therapies in patients
with ET in routine clinical practice. Additional objectives
include improving the understanding of the risks involved
in long-term use of cytoreductive agents in ET. The aim of
this analysis is to characterize the baseline features and
management of patients with ET aged [80 years, who
were enrolled in the EXELS study.
2 Design and Methods
2.1 Trial Design
This is an ongoing phase IV non-interventional post-
approval commitment study observing high-risk patients
with ET who are treated with cytoreductive therapy. The
EXELS study (ClinicalTrials.gov identifier NCT00567502;
Protocol: SPD422-401) is being conducted in 13 European
countries: Denmark, Finland, France, Germany, Greece,
Ireland, Italy, The Netherlands, Norway, Portugal, Spain,
Sweden and the United Kingdom. The first patient entered
the study in May 2005 following local ethics committee
approval at all participating centres. Predefined clinical
events and biological data (including full blood counts)
were collected from each patient at the time of registration
and every 6 months thereafter for 5 years, using an elec-
tronic data capture system. The last patient was registered
in April 2009 and the study will be completed in June
2014. This analysis was performed on a data-cut taken in
March 2011. The EXELS study is non-interventional and
no comparisons are made between groups due to the non-
interventional nature of the study.
2.2 Participants
Patients with a diagnosis of ET according to the World
Health Organization [1] and/or Polycythemia Vera Study
Group criteria [20] with one or more high-risk features
(patients [60 years of age; history of thrombohaemor-
rhagic events; initial platelet count [1000 9 109/L), and
receiving cytoreductive therapy, were eligible for study
inclusion. Exclusion criteria were limited to the contrain-
dications listed in the product information of the cytore-
ductive therapy. Written informed consent was obtained
from all patients before entering the study.
2.3 Treatment
As this was a non-interventional study, the choice of
cytoreductive therapy was determined prior to study reg-
istration and patients were managed according to local
practice at the discretion of the investigators. Data related
to predefined events (PDEs), suspected serious adverse
reactions (SSARs), platelet count and any changes to
medication were recorded at each 6-month update. Patients
with multiple events of the same PDE category were only
counted once for each treatment received. Thromboembo-
lic events were defined in this analysis as the following
PDEs: myocardial infarction (MI) and angina, stroke,
transient ischaemic attack (TIA), intermittent claudication/
digital ischaemia, and venous thromboembolic events. All
safety evaluations and procedures were performed in
accordance with routine clinical practice.
2.4 Statistical Methods
Ninety-five percent confidence intervals (CIs) for propor-
tions were calculated and assessed for statistical signifi-
cance using Chi-squared tests between reasons for
treatment switch. A repeated measures analysis of variance
(ANOVA) was used to determine whether the inclusion of
treatment-naı¨ve patients had affected the differences in
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platelet counts over time. The statistical software used was
SAS version 9.2 (SAS Institute, Cary, NC, USA).
3 Results
3.1 Patients
A total of 3,598 patients were enrolled in the EXELS study,
including 395 (11 %) very elderly (aged [80 years)
patients. Patient demographics and characteristics at study
registration are shown in Table 1. More than two-thirds
(68.6 %) of the very elderly patients were female. As
would be expected, a notable proportion of patients aged
[80 years had experienced a previous vascular or haem-
orrhagic event (42.2 %). Sixty-three of these patients
(16 %) were treatment-naı¨ve (defined as those who had
only recently started cytoreductive treatment of any kind,
within 6 months prior to registration).
3.2 Treatment
The treatments patients aged [80 years were receiving at
enrolment are presented in Fig. 1. HC and anagrelide
represent the two main cytoreductive treatments used as
monotherapy in 91.4 % of the very elderly patients in
EXELS. In the defined group, HC was most frequently
prescribed (82.8 %) and anagrelide use was much less
frequent (8.6 %). At enrolment into the EXELS study,
80.5 % (318/395) of the very elderly patients were
receiving their first cytoreductive treatment but only
3.46 % (11/395) were receiving anagrelide. In total,
69.4 % of the very elderly patients were receiving anti-
aggregatory therapy.
3.3 Blood Cell Counts
3.3.1 Platelet Count
Platelet counts showed an initial reduction in all age groups
from registration to 6 months, which was found to be
significantly driven by the start of cytoreductive therapy in
treatment-naı¨ve patients (ANOVA; p \ 0.001). Following
the initial reduction, platelet counts remained fairly con-
sistent at a median count of *430 9 109/L in the very
elderly patients (Fig. 2a).
3.3.2 Haemoglobin
The median haemoglobin (Hb) values remained relatively
stable in the range of 11.5–12.29 g/dL throughout the study
in patients aged [80 years (Fig. 2b).
3.3.3 Haematocrit
A slight variation over time (within 0.36–0.40) in median
haematocrit counts was observed in patients aged
[80 years (Fig. 2c).
3.3.4 White Blood Cells
A slight variation in the median white blood cell count
(between 5.6 and 7.1 9 109/L) was observed in the very
elderly patients over time (Fig. 2d).
It is important to note that the EXELS study is ongoing;
therefore, for the entire clinical laboratory data reported at
this data-cut, the n-numbers declined over time, as some
patients had not completed the full 60-month observation
period at the time of the data cut.
Table 1 Summary of
demographic and patient
characteristics at study
enrolment in patients aged
[80 years and the total EXELS
population
Patients with missing data:
a n = 2; b n = 15; c n = 29
CI confidence interval, Hb
haemoglobin, Hct haematocrit,
WBC white blood cells
Characteristic Age category
Age [80 years Total
Total,a n (%) 395 (11.0) 3,598
Female,b n (%) [95 % CI] 271 (68.6) [66.7–70.5] 2,194 (61.0)
Male,b n (%) [95 % CI] 124 (31.4) [26.8–36.2] 1,389 (38.6)
Haematological values, mean (SD)
Hb (g/dL) 11.96 (1.69) 12.87 (1.635)
Hct 0.37 (0.05) 0.39 (0.045)
WBC (9 109/L) 7.44 (4.57) 7.32 (4.075)
Platelets (9 109/L) 485.71 (197.99) 491.85 (227.84)
Treatment-naı¨ve,a n (%) [95 % CI] 63 (16.0) [12.5–19.9] 694 (19.3)
Anti-aggregatory therapy at
registration,a n (%) [95 % CI]
274 (69.4) [64.6–73.9] 2,505 (69.6)
Haemorrhagic and vascular
events prior to registration,c n (%)
[95 % CI]
166 (42.2) [37.3–47.3] 1,344 (37.4)
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3.4 Treatment Switching
The frequency and reasons for first treatment switch, since
study enrolment, are shown in Table 2. Investigators
determined the reason for switching therapy according to
their best clinical judgement. Very elderly patients were
more likely to be switched from anagrelide than from HC
(47.1 vs. 17.4 %; 95 % CI for difference in proportion
12.4–46.9; Chi-squared test p \ 0.001). The Kaplan-Meier
plots illustrate the time to first treatment switch based on
survival analysis methodology (Fig. 3). In the total EXELS
population, more patients had their therapy switched
because of intolerance rather than loss of efficacy (28.1 vs.
12.3 %; 95 % CI for difference in proportion 12.2–19.3;
Chi-squared test p \ 0.001). In patients aged [80 years,
the main reason for switch was intolerance/side effects.
However, almost one-third of patients switched for ‘other’
reasons, which were largely due to lack of control of
platelet counts and reductions in counts of white blood
cells or Hb (data not shown). The reasons for first switch
were similar between HC and anagrelide treatment in the
overall study population. However, in very elderly patients,
0/16 reported treatment with anagrelide was non-effica-
cious compared with 8/57 (14 %) patients receiving HC,
and 7/16 (43.8 %) anagrelide patients switched due to
intolerance versus 18/57 (31.6 %) patients receiving HC.
3.5 Predefined Clinical Events
The total numbers of predefined clinical events (PDEs),




















Fig. 1 Treatment at registration in patients aged [80 years. ‘Other’
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Fig. 2 Evaluation of mean blood cell counts over time in patients aged [80 years: (a) platelets, (b) haemoglobin, (c) haematocrit, (d) white
blood cells
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[80 years group, 27.3 % of patients experienced at least one
PDE. The most common PDEs reported in the very elderly
age group were death (non-PDE related; 11.1 %), other
cardiovascular (CV) symptoms (5.8 %), haematological
transformation (3.8 %), congestive heart failure (CHF;
3.3 %), and MI and angina (2.8 %). There was no association
observed between treatment received and occurrence of CHF
or CV symptoms PDEs (data not shown).
The most common type of haematological transforma-
tion that occurred in the total EXELS population was
myelofibrosis (n = 49, 1.4 %), followed by acute leukae-
mia (n = 37, 1.0 %) and ‘other’, including transformation
to myelodysplasia (n = 27, 0.8 %). In patients aged
[80 years, acute leukaemia (n = 7, 1.8 %) and myelofi-
brosis (n = 4, 1.0 %) were also the most frequent
transformations.
Table 2 Treatment switching
in patients aged [80 years and
the total EXELS population
CI confidence interval, HC
hydroxycarbamide, NA not
applicable
a Values are expressed as n (%)
[95 % CI]
b Patients with missing data:
n = 2
Variable Age categorya
Age [80 years Total
Frequency of first switchb
Switch from any monotherapy 91/395 (23.0) [18.9–27.2] 902/3,596 (25.1)
Switch from HC monotherapy 57/327 (17.4) [13.3–21.5] 455/2,340 (19.4)
Switch from anagrelide monotherapy 16/34 (47.1) [30.3–63.8] 237/792 (30.0)
Reasons for first switch from HC
Intolerance/side effects 18/57 (31.6) [19.5–43.6] 127/455 (27.9)
Non-efficacious 8/57 (14.0) [5.0–23.1] 55/455 (12.1)
Subject preference 1/57 (1.8) [0–5.2] 9/455 (2.0)
Other 17/57 (29.8) [17.9–41.7] 133/455 (29.2)
Missing 10/57 (17.5) [7.7–27.4] 138/455 (30.3)
Unknown 5/57 (8.8) [1.4–16.1] 10/455 (2.2)
Reasons for first switch from anagrelide
Intolerance/side effects 7/16 (43.8) [19.4–68.1] 69/237 (29.1)
Non-efficacious 0/16 (0.0) [NA] 31/237 (13.1)
Subject preference 1/16 (6.3) [0–18.1] 13/237 (5.5)
Other (including economic) 6/16 (37.5) [13.8–61.2] 47/237 (19.8)
Missing 2/16 (12.5) [0–28.7] 76/237 (32.1)



































Fig. 3 Kaplan–Meier estimates
for first treatment switch in
patients aged [80 years
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Thromboembolic events were experienced in 6.3 %
(25/395) of patients [80 years and 5.2 % (186/3,596) of
the total EXELS cohort (Table 3).
4 Discussion
4.1 Patients
This prospective observational study of 3,598 patients with
ET includes, to our knowledge, the largest population of
patients with ET studied to date, including 395 patients
aged[80 years. Sparse data are available on the treatment
of very elderly patients with ET. Notably, Palandri et al.
reported data on 118 patients with ET aged[75 years, who
they classified as very elderly [19]. They retrospectively
analysed 326 consecutive patients with ET diagnosed at
[60 years, although no patients aged [75 years received
anagrelide and, perhaps because of this, only 5.3 % dis-
continued HC because of adverse effects. The information
collected from EXELS provides valuable insight into the
treatment of these very elderly patients in clinical practice.
4.2 Treatment
The vast majority of very elderly patients were receiving
HC and although anagrelide was the next most frequently
used agent, the proportion of patients receiving it was low
(8.6 %). These results suggest that the expert recommen-
dations for ET therapy are applied by physicians across
Europe [8].
The proportion of patients who were receiving their first
cytoreductive treatment, at the time of entering the EXELS
study, increased with patient age. The high proportion of
very elderly patients receiving first-line HC is probably due
to the fact that there is broad agreement among physicians
that HC is the treatment of choice for very elderly patients
and because HC is well tolerated in general. Concerns
regarding the potential leukaemogenicity of HC are less
relevant for older patients than younger ones, since their
life expectancy is reduced. Furthermore, physicians may be
reluctant to use anagrelide in older patients due to the
recognized inotropic effects [9], making HC the agent of
choice and options for switch limited. However, our results
have shown that anagrelide can be effective and well tol-
erated, and provides a good alternative treatment option to
busulphan, in very elderly patients for whom HC is
unsuitable. Indeed, Italian guidelines recommend the con-
tinuation of anagrelide in patients aged [60 years for as
long as it continues to be effective [26].
4.3 Blood Cell Counts
The initial reduction in platelet counts that was observed in
all age groups was shown to be significantly affected by the
treatment-naı¨ve population. When these patients were
Table 3 Numbers of patients with predefined events (PDEs) and numbers of PDEs by age category
Variable Age category
Age [80 years (n = 395) Total (n = 3596)a
n (%) [95 % CI] Events n (%) Events
All PDEs reported 108 (27.3) [22.9–31.7] 167 636 (17.7) 911
Notable individual PDEs
MI and angina 11 (2.8) [1.2–4.4] 13 59 (1.6) 66
Stroke 5 (1.3) [0.2–2.4] 6 49 (1.4) 55
TIA 4 (1.0) [0.0–2.0] 6 33 (0.9) 38
Intermittent claudication/digital ischaemia 2 (0.5) [0.0–1.2] 2 12 (0.3) 15
Venous thromboembolic events 7 (1.8) [0.5–3.1] 8 44 (1.2) 49
Thromboembolic eventsb total 25 (6.3) [3.9–8.7] 35 186 (5.2) 223
Congestive heart failure 13 (3.3) [1.5–5.1] 14 35 (1.0) 36
Major haemorrhage 10 (2.5) [1.0–4.1] 12 58 (1.6) 69
Other cardiovascular symptoms 23 (5.8) [3.5–8.1] 29 129 (3.6) 159
Transformationc 15 (3.8) [1.9–5.7] 15 106 (2.9) 113
Non-PDE death 44 (11.1) [8.0–14.2] 44 103 (2.9) 103
CI confidence interval, MI myocardial infarction, TIA transient ischaemic attack
a Patients with missing data: n = 2
b Thromboembolic events defined as: MI and angina, stroke, TIA, intermittent claudication/digital ischaemia, venous thromboembolic events.
Note: Some patients experienced more than one thromboembolic event
c Transformation to: acute leukaemia, myelodysplasia, myelofibrosis and ‘other’
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removed from the analysis, the platelet counts remained
fairly consistent.
The data suggest that the ‘target platelet count’, the point
at which platelet counts are allowed to bottom-out, is
*450 9 109/L for the very elderly patients in clinical
practice. The criteria for a complete haematological
response with ET therapy published by the European Leu-
kemiaNet (ELN) include a target platelet count below
400 9 109/L [8]. It is a positive finding that these very
elderly patients achieved levels that were close to target.
Physicians may be particularly stringent about achieving
low platelet counts in very elderly patients as this population
has a higher incidence of previous vascular events (also
shown in this study), which is a major risk factor for
recurrent thrombosis. The ELN guidelines also include the
following criteria in the definition of complete haemato-
logical response: normal spleen size on imaging, white
blood cell count below 10 9 109/L, and absence of disease-
related symptoms [8]. However, since EXELS predates the
publication of these guidelines, these criteria were not
considered in the study design and these data were not col-
lected. Response rates were judged only on platelet levels.
Although anaemia has been reported with both of the
major therapeutic agents used in the treatment of myelo-
proliferative neoplasms, the Hb values did not change over
time in these patients. Anaemia is defined as a Hb value of
\12 g/dL in adult females and\13 g/dL in adult males [21].
The mean baseline Hb levels in the very elderly population
were 12.0 g/dL, with the median values ranging from 11.5 to
12.3 g/dL over time. Since more than two-thirds of these
patients were female, the Hb levels were on the low side of
the normal range, which may be due to the large proportion
of patients receiving treatment with HC [22–25].
4.4 Treatment Switching
The proportion of very elderly patients switching from
anagrelide was 47.1 vs. 17.4 % from HC. The reason for
first switch from HC or anagrelide was more often because
of intolerance than loss of efficacy. Similar proportions of
patients switched from HC because of lack of efficacy in
our study and that of Palandri et al [19]. Elderly patients
have more frequent cardiac abnormalities than younger
patients, which may make them more prone to switch
treatment if they experience tachycardia or palpitations
while receiving anagrelide. A further explanation for high
levels of switching from anagrelide in older patients may
be that various national guidelines suggest that HC, pipo-
broman or busulphan are preferable for the treatment of the
oldest patients with ET [8, 26]. However, the small number
of very elderly patients treated with anagrelide in EXELS
(n = 34) precludes the formation of any strong conclusions
concerning treatment switching. Low rates of switching
therapy because of inefficacy (Table 2), along with almost
normal target platelet count observed in patients[80 years,
show that cytoreductive therapy in very elderly patients is
effective. Indeed, tolerance is the main issue in managing
patients of all ages with ET in clinical practice and is a
particular concern in very elderly patients.
4.5 Predefined Clinical Events
Overall, 108 patients aged[80 years experienced a total of
167 PDEs, including vascular complications (n = 90),
haematological transformation (to acute leukaemia or
myelofibrosis; n = 15) and non-PDE deaths (n = 44).
However, no new safety concerns were observed in these
patients. Thromboembolic events happen in patients with
ET, irrespective of the use of cytoreductive therapy, and
elderly patients are also recognized to have a slightly
increased risk [18]. The very elderly patients in the study
by Palandri et al. also experienced a greater thrombotic risk
than those aged \75 years. [19] Although data on the
incidence of angina in a non-MPN population are available
[27], uncertainties concerning diagnostic definitions and
data collection principles make comparisons with the EX-
ELS population unreliable.
The incidence of stroke and TIA in the very elderly
patients in the EXELS study was 1.3 and 1.0 %, respec-
tively. In comparison, across Europe between 2001 and
2009, stroke and TIA accounted for 0.45 % of annual
hospital admissions in adults aged C80 years (0.29 and
0.15 % each, respectively) [27]. Therefore, these events
were substantially more frequent in the very elderly pop-
ulation in EXELS than the European elderly population.
Diseases of the circulatory system (not including angina,
MI, ischaemic or pulmonary heart disease, cardiac
arrhythmias, cerebrovascular diseases, atherosclerosis or
varicose veins), which included pulmonary embolism and
deep vein thrombosis, occurred in less than 0.3 % of
European adults aged C80 years annually between 2001
and 2009 [27]. In comparison, venous thromboembolisms
occurred in 1.2 % of all patients in EXELS and 1.8 % of
those aged [80 years. Therefore, the risk of thromboem-
bolisms was substantially raised in patients in EXELS and
particularly so in those aged [80 years versus the overall
European population.
Of note, similar proportions of patients aged [80 years
and patients in the overall EXELS population experienced
thromboembolic events.
5 Conclusion
In conclusion, here we describe an analysis of very elderly
patients from the largest ever observational study of
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patients with ET, providing new data on ET management
of these patients in clinical practice. The haematological
response and normalization of platelet counts achieved
with cautious management of these patients is particularly
promising. It is also of interest to note that intolerance to
cytoreductive therapy is the main reason for treatment
switch, not only in these very elderly patients but in
patients of all ages.
To summarize, well-tolerated and effective cytoreductive
therapy has been achieved in patients aged [80 years by
following individual treatment modalities that appear in
agreement with the recent ELN guidelines. These findings
will be confirmed once the study is completed in June 2014.
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